Read by QxMD icon Read

wet amd

Razek Georges Coussa, Susan M Wakil, Hady Saheb, David E Lederer, Karin M Oliver, Devinder P Cheema
Purpose: To report the occurrence and management of severe infectious scleritis in a 75 year-old woman following intravitreal ranibizumab injection. Observations: A 75 year-old monocular woman receiving monthly intravitreal ranibizumab injection for wet age related macular degeneration in the left eye presented with severe dull pain, decreased vision, and scleral melt with discharge 2 weeks after her last injection. The dilated fundus exam was devoid of vitritis...
April 2017: American Journal of Ophthalmology Case Reports
Hidenori Takahashi, Yuji Inoue, Xue Tan, Satoru Inoda, Shinichi Sakamoto, Yusuke Arai, Yasuo Yanagi, Yujiro Fujino, Hidetoshi Kawashima
Purpose: To investigate the correlation between visual acuity and central macular thickness (CMT) and choroidal thickness (CCT) in patients with wet age-related macular degeneration (AMD). Methods: In this retrospective analysis, 14 eyes that received >10 ranibizumab injections (based on pro re nata [PRN] regimen) and maintained initial visual acuity gain were analyzed. The following 5 parameters were measured at the foveal center: CMT (distance from the inner limiting membrane [ILM] to Bruch's membrane); central retinal thickness (CRT; distance from the ILM to the inner limit of the retinal pigment epithelium or subretinal fluid [SRF]); SRF thickness (SRFT); pigment epithelium detachment thickness (PEDT); and CCT...
2018: Clinical Ophthalmology
Deanna J Taylor, Nicholas D Smith, Alison M Binns, David P Crabb
PURPOSE: There is a well-established research base surrounding face recognition in patients with age-related macular degeneration (AMD). However, much of this existing research does not differentiate between results obtained for 'wet' AMD and 'dry' AMD. Here, we test the hypothesis that face recognition performance is worse in patients with dry AMD compared with visually healthy peers. METHODS: Patients (>60 years of age, logMAR binocular visual acuity 0.7 or better) with dry AMD of varying severity and visually healthy age-related peers (controls) completed a modified version of the Cambridge Face Memory Test (CFMT)...
February 27, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
Luis Fernando Hernández-Zimbrón, Ruben Zamora-Alvarado, Lenin Ochoa-De la Paz, Raul Velez-Montoya, Edgar Zenteno, Rosario Gulias-Cañizo, Hugo Quiroz-Mercado, Roberto Gonzalez-Salinas
Age-related macular degeneration (AMD) is a well-characterized and extensively studied disease. It is currently considered the leading cause of visual disability among patients over 60 years. The hallmark of early AMD is the formation of drusen, pigmentary changes at the macula, and mild to moderate vision loss. There are two forms of AMD: the "dry" and the "wet" form that is less frequent but is responsible for 90% of acute blindness due to AMD. Risk factors have been associated with AMD progression, and they are taking relevance to understand how AMD develops: (1) advanced age and the exposition to environmental factors inducing high levels of oxidative stress damaging the macula and (2) this damage, which causes inflammation inducing a vicious cycle, altogether causing central vision loss...
2018: Oxidative Medicine and Cellular Longevity
Pasi Vottonen
No abstract text is available yet for this article.
February 2018: Acta Ophthalmologica
Luis Hernandez, Tereza Lanitis, Clifford Cele, Hector Toro-Diaz, Andrea Gibson, Andreas Kuznik
BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of vision loss in the United States. The most severe vision loss occurs in patients with neovascular AMD, known as wet AMD (wAMD). The most commonly used antivascular endothelial growth factor (VEGF) therapies approved by the FDA to treat patients with wAMD are ranibizumab, 0.5 mg administered by intravitreal injection once a month (approximately every 28 days), and intravitreal aflibercept injection (IAI), 2 mg every 4 weeks (monthly) for the first 12 weeks (3 months), followed by IAI 2 mg once every 8 weeks (2 months)...
February 16, 2018: Journal of Managed Care & Specialty Pharmacy
Shang Chen, Yue Zhou, Lichun Zhou, Yanhui Guan, Yu Zhang, Xiuzhen Han
Choroidal neovascularization (CNV) is the hallmark of late-staged wet age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a key component in the development and progression of wet AMD. DMBT, 6,6'-bis(2,3-dimethoxybenzoyl)-α,α-D-trehalose, had been proved that it could suppress tumor angiogenesis and metastasis by inhibiting production of VEGF. But the effects of DMBT on CNV were not known. This study was to investigate effects and mechanisms of DMBT on CNV in vitro and in vivo...
February 14, 2018: Molecular and Cellular Biochemistry
Katja Hatz, Frank Zimmermann, Dimitrios Kardamakis, Emmanouil Lazaridis, Cengiz Türksever, Jörg Binder, Alexandros Papachristofilou, Christian Prünte
BACKGROUND AND OBJECTIVE: To evaluate the effectiveness and safety of low-energy stereotactic radiotherapy (SRT) combined with anti-vascular endothelial growth factor (VEGF) treatment following a treat-and-extend regimen (TER) in wet age-related macular degeneration (AMD). PATIENTS AND METHODS: Before/after SRT, the authors compared retrospective consecutive case series of 50 patients requiring frequent anti-VEGF treatment (every 4 or 6 weeks) in wet AMD, treated with a single session of SRT and TER (same manner pre/post-SRT)...
February 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
Sidney Schechet, Seenu M Hariprasad, Asadolah Movahedan, Dimitra Skondra
No abstract text is available yet for this article.
February 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
Sandra Petrus-Reurer, Hammurabi Bartuma, Monica Aronsson, Sofie Westman, Fredrik Lanner, Anders Kvanta
Geographic atrophy (GA), the late stage of dry age-related macular degeneration is characterized by loss of the retinal pigment epithelial (RPE) layer, which leads to subsequent degeneration of vital retinal structures (e.g., photoreceptors) causing severe vision impairment. Similarly, RPE-loss and decrease in visual acuity is seen in long-term follow up of patients with advanced wet age-related macular degeneration (AMD) receiving intravitreal anti-vascular endothelial growth factor (VEGF) treatment. Therefore, on the one hand, it is fundamental to efficiently derive RPE cells from an unlimited source that could serve as replacement therapy...
January 22, 2018: Journal of Visualized Experiments: JoVE
Symantas Ragauskas, Eva Kielczewski, Joseph Vance, Simon Kaja, Giedrius Kalesnykas
Laser-induced choroidal neovascularization (CNV) is a well-established model to mimic the wet form of age-related macular degeneration (AMD). In this protocol, we aim to guide the reader not simply through the technical considerations of generating laser-induced lesions to trigger neovascular processes, but rather focus on the powerful information that can be obtained from multimodal longitudinal in vivo imaging throughout the follow-up period. The laser-induced mouse CNV model was generated by a diode laser administration...
January 21, 2018: Journal of Visualized Experiments: JoVE
Parul Desai, Darwin C Minassian, Angela Reidy, Naomi Allen, Cathie Sudlow
OBJECTIVES: To estimate the number of new cases of age-related macular degeneration, cataract and glaucoma accruing in the UK Biobank cohort, over a period of 25 years from time of recruitment. Our secondary objective was to assess the statistical power of nested case-control studies of these eye diseases. We aimed to provide quantitative information relevant to UK Biobank's eye disease case ascertainment efforts and to the potential for UK Biobank-based research into the causes of eye disease...
February 6, 2018: British Journal of Ophthalmology
Xavier Corveleyn, Quentin Lenoble, Sébastien Szaffarczyk, Thi Ha Chau Tran, Muriel Boucart
SIGNIFICANCE: Vision is paramount for motor actions directed toward objects. Vision allows not only the identification of objects and their shape and spatial location, but also the adaptation of our movement when it arrives on the object. These findings show that vision deficits, as in age-related macular degeneration (AMD), can lead to reaching and grasping deficits. PURPOSE: Few studies have investigated reaching and grasping in patients with AMD. They showed a deficit in the execution of motor actions in people with AMD, even though these people do not mention difficulties in their daily lives...
February 8, 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
Mohammad Hossein Jabbarpoor Bonyadi, Mehdi Yaseri, Homayoun Nikkhah, Mortaza Bonyadi, Rahman Nazari, Masoud Soheilian
PURPOSE: We designed this meta-analysis to pool studies which have analyzed both CFH (Y402H or I62V) and ARMS2 A69S in the same samples to compare the effect of CFH and ARMS2 in neovascular AMD. METHODS: Relevant studies identified and reviewed separately in order to select those for inclusion. Included studies had genotype data of studied groups for both ARMS2 A69S and CFH. To modify the heterogeneity in the variables, we used random effects model. Meta-analysis was performed using STATA...
February 8, 2018: International Ophthalmology
Hyung-Bin Lim, Jae-Yun Sung, Seung-Il Ahn, Young-Joon Jo, Jung-Yeul Kim
SIGNIFICANCE: Peripapillary retinal nerve fiber layer (RNFL) thickness measurements may be influenced by the range and severity of lesions that are observed distinctively in each retinal disease. PURPOSE: We investigated the effects of various macular (central serous chorioretinopathy, macular hole, epiretinal membrane, wet age-related macular degeneration) and retinal vascular (branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema) diseases on peripapillary RNFL thickness measurements using spectral-domain optical coherence tomography...
March 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
Christopher M Adams, Karen Anderson, Gerald Artman, Jean-Claude Bizec, Rosemarie Cepeda, Jason Elliott, Elizabeth Fassbender, Malay Ghosh, Shawn Hanks, Leo A Hardegger, Vinayak P Hosagrahara, Bruce Jaffee, Keith Jendza, Nan Ji, Leland Johnson, Wendy Lee, Donglei Liu, Fang Liu, Debby Long, Fupeng Ma, Nello Mainolfi, Erik L Meredith, Karl Miranda, Yao Peng, Stephen Poor, James Powers, Yubin Qiu, Chang Rao, Siyuan Shen, Jeremy M Sivak, Catherine Solovay, Peter Tarsa, Amber Woolfenden, Chun Zhang, Yiqin Zhang
A noninvasive topical ocular therapy for the treatment of neovascular or "wet" age-related macular degeneration would provide a patient administered alternative to the current standard of care, which requires physician administered intravitreal injections. This manuscript describes a novel strategy for the use of in vivo models of choroidal neovascularization (CNV) as the primary means of developing SAR related to efficacy from topical administration. Ultimately, this effort led to the discovery of acrizanib (LHA510), a small-molecule VEGFR-2 inhibitor with potency and efficacy in rodent CNV models, limited systemic exposure after topical ocular administration, multiple formulation options, and an acceptable rabbit ocular PK profile...
February 5, 2018: Journal of Medicinal Chemistry
Justus G Garweg, Johanna J Zirpel, Christin Gerhardt, Isabel B Pfister
PURPOSE: Real-life studies on long-term functional outcome of anti-VEGF treatment for wet age-related macular degeneration (wAMD) are limited. We therefore assessed the 10-year outcomes in our patients. METHODS: In this retrospective study, all patients with newly diagnosed wAMD that had received minimally three intravitreal injections between 2007 and 2012 and a follow-up of ≥48 months were included. Primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time...
February 3, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
Varun Chaudhary, Michael Brent, Wai-Ching Lam, Robert Devenyi, Joshua Teichman, Michael Ying-Kit Mak, Harneel Kaur, Joshua Barbosa, Ronald Carter, Forough Farrokhyar
No abstract text is available yet for this article.
January 26, 2018: Ophthalmologica. Journal International D'ophtalmologie
Deborah Cohen
No abstract text is available yet for this article.
January 24, 2018: BMJ: British Medical Journal
Tim J Enz, Livia Faes, Lucas M Bachmann, Michael A Thiel, Jeremy P Howell, Sophie C Boehni, Mario Bittner, Martin K Schmid
PURPOSE: To evaluate differences in postoperative central macular thickness, central macular volume, corrected distance visual acuity (CDVA), and number of intravitreal anti-vascular endothelial growth factor (VEGF) injections between conventional and femtosecond laser-assisted cataract surgery in wet age-related macular degeneration (AMD). SETTING: Tertiary referral center, Lucerne, Switzerland. DESIGN: Retrospective case series. METHODS: Consecutive patients with AMD and cataract were enrolled between January 2010 and December 2015...
January 17, 2018: Journal of Cataract and Refractive Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"